scholarly journals Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

2012 ◽  
Vol 18 (2) ◽  
pp. 280-288 ◽  
Author(s):  
Philippe Armand ◽  
Haesook T. Kim ◽  
Mei-Jie Zhang ◽  
Waleska S. Perez ◽  
Paola S. Dal Cin ◽  
...  
Keyword(s):  
Complete Remission ◽  
Acute Myelogenous Leukemia ◽  
Research Study ◽  
Allogeneic Transplantation ◽  
Marrow Transplant ◽  
Myelogenous Leukemia ◽  
Blood And Marrow Transplant ◽  
Acute Myelogenous

scholarly journals Prognostic Impact of Peripheral Blood Count Recovery and Cytogenetic Remission Prior to Reduced Intensity Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndromes

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3210-3210 ◽  
Author(s):  
Moussab Damlaj ◽  
Hassan B Alkhateeb ◽  
Mehrdad Hefazi ◽  
Daniel K. Partain ◽  
Aref Al-Kali ◽  
...  
Keyword(s):  
Overall Survival ◽  
Complete Remission ◽  
Acute Myelogenous Leukemia ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Transplant Outcomes ◽  
Acute Myelogenous ◽  
The Impact ◽  
Reduced Intensity ◽  
Count Recovery

Abstract Background:Morphologic complete remission (CR) is the gold standard for assessing response in acute myelogenous leukemia (AML). CR with incomplete count recovery (CRi) and CR with incomplete platelet recovery (CRp) are associated with inferior overall survival post induction therapy (Walter et al, JCO 2010 and Chen et al, JCO 2015). Furthermore, residual cytogenetic disease is associated with a higher relapse compared with patients with cytogenetic CR (CCR; Chen et al, JCO 2011). There is a paucity of literature regarding the impact of CRi, CRp and CCR prior to allogeneic transplantation. Aim:To study the impact of CRi, CRp and CCR and their impact on relapse incidence (RI), non-relapse mortality (NRM) and overall survival (OS) in reduced intensity allogeneic stem cell transplantation (RIC-SCT). Methods:After due IRB approval, patients (pts) with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) who received RIC-SCT at our institution between 2008-2014 were identified. All clinical and pathologic data were retrospectively extracted. CR, CRi, CRp and CCR were defined in accordance to the international working group definition. Categorical and continuous variables were analyzed using Pearson's chi-squared and Wilcoxon/Kruskal-Wallis, respectively. Survival estimates were calculated using the kaplan-meier and log-rank test. RI was estimated on a competing event analysis using Grey's model. Cox proportional regression was used to compute hazard ratios (HR). Results: A. Baseline characteristics: A total of 134 patients were identified. A total of 70 (52%) were in CR, 40 (30%) in CRi and 24 (18%) in CRp. 129 patients had evaluable cytogenetic data pre-SCT; 81 (63%) were in CCR and 48 (37%) had persistent cytogenetic disease. Baseline patient, disease and transplant characteristics stratified by peripheral count recovery pre-SCT are shown (Table 1). Significantly more patients in CR had higher KPS, higher proportion AML diagnosis, more likely to be in first complete remission (CR1), higher rate of cytogenetic CR and a higher proportion of minor ABO mismatched donor. No other significant variables were identified between the three cohorts. B. Transplant outcomes: Median follow up of the entire cohort was 41.9 months and the 2-yr OS, RI and NRM were 61.7%, 25.7% and 21.9%. Patients in CR, CRi and CRp had a similar 2-year rates of RI (26.3%, 18.4% and 28.9%, respectively; p = 0.66), 2-year NRM (20.5%, 38.8% and 22.1%, respectively; p = 0.18) and 2-year OS (61.8%, 55.1% and 58.6%, respectively; p = 0.82). RI was significantly lower for patients in CCR pre-SCT with HR 0.25 (95% CI 0.11-0.51 p = 0.0001) without a difference in overall survival HR 0.68 (0.41-1.15; p = 0.14). However, we observed a similar RI in CR, CRi and CRp patients who had persistent cytogenetic disease pre-SCT (p = 0.55). The outcome remained similar between strata after excluding MDS patients (data not shown). Conclusion: We observed equivalent post-transplant outcomes between CR, CRi and CRp despite the presence of persistent cytogenetic disease. This suggests that RIC SCT had a role in mitigating the negative prognosis associated incomplete hematologic recovery. These findings have implications as physicians may not need to postpone SCT to await count recovery. This important question should be further validated in a larger cohort of patients. Figure 1. Figure 1. Figure 2. Figure 2. Disclosures Al-Kali: Novartis: Research Funding.

Allogeneic transplantation for advanced acute myelogenous leukemia: The value of complete remission.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 7033-7033
Author(s):  
Daniel Jordan Weisdorf ◽  
Heather R Millard ◽  
Mary M. Horowitz ◽  
Mary Eapen ◽  
Parvinder Hyare ◽  
...  
Keyword(s):  
Complete Remission ◽  
Acute Myelogenous Leukemia ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous

Aging, Acute Myelogenous Leukemia, and Allogeneic Transplantation: Do They Belong in the Same Sentence?

2009 ◽  
Vol 9 (4) ◽  
pp. 289-297 ◽  
Author(s):  
Stefan O. Ciurea ◽  
Morgani Rodrigues ◽  
Sergio Giralt ◽  
Marcos de Lima
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Allogeneic Transplantation ◽  
Myelogenous Leukemia ◽  
Acute Myelogenous

scholarly journals Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update

Blood ◽  
1983 ◽  
Vol 62 (2) ◽  
pp. 315-319 ◽  
Author(s):  
HJ Weinstein ◽  
RJ Mayer ◽  
DS Rosenthal ◽  
FS Coral ◽  
BM Camitta ◽  
...  
Keyword(s):  
Complete Remission ◽  
Maintenance Therapy ◽  
Induction Chemotherapy ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Kaplan Meier ◽  
High Incidence ◽  
Acute Myelogenous ◽  
Leukemia In Children

Abstract We designed a protocol (VAPA) that featured 14 mo of intensive postremission induction chemotherapy in an effort to improve remission durations for patients with acute myelogenous leukemia (AML). One hundred and seven patients under 50 yr of age were entered into this study. The rate of complete remission is 70%. A Kaplan-Meier analysis of patients entering remission predicts that 56% +/- 7% (+/-SE) of patients less than 18 yr and 45% +/- 9% of patients aged 18–50 yr will remain in remission at 3 yr (median follow-up is 43 mo). Patients with the monocytic subtype had a statistically significant shorter duration of remission (2-sided p less than 0.05). There was a high incidence of primary CNS relapse in children. Thirty-one of 41 patients who completed the regimen remain in remission without maintenance therapy. We conclude that the VAPA protocol continues to offer a promising approach to treatment of AML.

Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

2020 ◽  
Vol 61 (13) ◽  
pp. 3120-3127 ◽  
Author(s):  
Catherine Kendall Major ◽  
Hagop Kantarjian ◽  
Koji Sasaki ◽  
Gautam Borthakur ◽  
Tapan Kadia ◽  
...  
Keyword(s):  
Complete Remission ◽  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Landmark Analysis ◽  
Acute Myelogenous
Sign in / Sign up

Export Citation Format

Share Document